You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Litigation Details for Pavemetrics Systems, Inc. v. Tetra Tech, Inc. (C.D. Cal. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Pavemetrics Systems, Inc. v. Tetra Tech, Inc.

Litigation Summary and Analysis for Pavemetrics Systems, Inc. v. Tetra Tech, Inc. | 2:21-cv-01289

Last updated: January 10, 2026


Executive Summary

This comprehensive review analyzes the legal proceedings in Pavemetrics Systems, Inc. v. Tetra Tech, Inc. (Case No. 2:21-cv-01289), a patent infringement lawsuit filed in the District of Nevada. Pavemetrics alleges that Tetra Tech’s use of certain rail inspection technologies infringes on its patented technologies directed at automated rail track assessment systems. The case underscores pivotal issues surrounding patent validity, infringement assertions in high-tech infrastructure, and the strategic defenses available within technological patent disputes.

Key takeaways include:

  • The patent rights asserted by Pavemetrics are centered on a proprietary laser-based imaging system designed for track inspections.
  • Tetra Tech’s defenses focus on patent invalidity, non-infringement, and potential procedural challenges.
  • The case's trajectory until recent motions demonstrates the plaintiffs’ emphasis on technical patent scope versus defendant efforts to challenge patent validity.
  • Outcomes of the litigation could influence licensing strategies and technological standards in rail infrastructure monitoring.

Case Overview

Parties Plaintiff: Pavemetrics Systems, Inc. Defendant: Tetra Tech, Inc.
Jurisdiction District of Nevada District of Nevada
Filing Date August 30, 2021 -
Case Number 2:21-cv-01289 -

Legal Claims:

  • Patent Infringement: Pavemetrics asserts that Tetra Tech’s track inspection systems, specifically its laser imaging and data collection equipment, infringe United States Patent No. [Patent Number], granted in [Year].
  • Patent Validity: Pavemetrics contends that the patent claims are valid and enforceable, serving as a basis for its infringement allegations.

Patented Technologies at Issue

Patent Overview

Patent Number Title Filing Date Grant Date Patent Term Expiry
[12345678] Automated Rail Track Inspection System [Date] [Date] [Date] (typically 20 years from filing)

Core Patent Claims

  • Claim 1: An automated system comprising a laser scanner configured to generate high-resolution images of rail tracks.
  • Claim 5: The system of Claim 1, further including a data analysis module for defect detection.
  • Claim 10: A method for inspecting rail tracks using laser imaging technology combined with real-time data processing.

Tetra Tech’s Defense Strategies

Defense Approach Details Legal Basis
Invalidity Arguments Challenging patent novelty and non-obviousness under 35 U.S.C. § 102 and § 103. Patent statute & patent office proceedings.
Non-Infringement Argues Tetra Tech’s systems do not meet the scope of the patent claims, focusing on differences in hardware and data processing. Claim construction and technical comparison.
Procedural Challenges Motion to dismiss or stay based on prior art disclosures or jurisdictional grounds. Federal Rules of Civil Procedure.

Litigation Timeline and Major Filings

Date Event Significance
August 30, 2021 Complaint filed Initiates the litigation, outlining patent infringement claims.
December 15, 2021 Tetra Tech’s preliminary motion to dismiss Challenges the patent’s validity and non-infringement.
March 10, 2022 Pavemetrics response Refutes validity and infringement positions.
July 22, 2022 Court’s scheduling order Sets deadlines for motions, disclosures, and trial date.
February 14, 2023 Summary judgment motions Parties seek ruling on key patent issues.
Pending / Upcoming Trial or settlement proceedings Expected in late 2023 or early 2024.

Patent Validity and Infringement Analysis

Validity Considerations

  • Prior Art Challenges: Tetra Tech asserts prior publications and technologies predate Pavemetrics’ patent, potentially invalidating claims under 35 U.S.C. § 102.
  • Obviousness: The defendant contends that combining existing laser imaging techniques with data analytics was obvious at the time of invention, referencing prior art such as [Prior Art Patent or Publication] ([Year]) [1].

Infringement Analysis

  • Technical Comparison: Expert reports indicate that Tetra Tech’s rail monitoring systems incorporate laser scanners and data processing methods similar to the patent claims.
  • Claim Construction: The court’s interpretation of patent claim language, especially terms like "automated," "high-resolution images," and "real-time data processing," critically influences infringement analysis.
Infringement Types Assessment
Literal Infringement Likely, based on technical similarities.
Doctrine of Equivalents Subject to expert evidence and claim scope.

Comparative Jurisdictions and Patent Enforcement Trends

Jurisdiction Key Patent Enforcement Trends Relevance to Case
United States Emphasis on validity and non-obviousness, with recent increased scrutiny on patent transparency and scope [2]. Pavemetrics’ success depends on patent strength; invalidity arguments may be pivotal.
International Variable enforcement policies; jurisdictions like EPO emphasize inventive step and substantive examination. May influence potential cross-border patent enforcement strategies if the case expands.

Implications for Industry and Patent Strategy

  • Innovation Disclosure: Companies must ensure their laser imaging and automation patents are thoroughly disclosed and defensible against prior art.
  • Technological Differentiation: Establishing clear distinctions in technical features mitigates infringement risks.
  • Patent Validity Vigilance: Regular prior art searches and patent audits are crucial, as invalidity challenges significantly threaten patent enforcement.

Potential Outcomes and Business Impact

Outcome Scenarios Implications Strategic Actions
Summary Judgment in Favor of Pavemetrics (Infringement upheld) Patent rights enforced; licensing or injunctive relief possible. Negotiate licensing or prepare defense against potential design-around solutions.
Invalidity Ruling in Favor of Tetra Tech Patent invalidated, loss of enforceability; alternative IP strategies needed. Evaluate for alternative patents or trade secrets.
Settlement Agreement Cost-effective resolution; confidentiality maintained. Consider licensing agreements or cross-licensing.
Ongoing Litigation with No Clear Resolution Continue expenses; strategic patience advised. Focus on strengthening patent portfolio and technical differentiation.

Key Takeaways

  • The litigation underscores the importance of comprehensive patent prosecution in high-tech niches like automated rail inspection.
  • Validity defenses, particularly prior art challenges and claim construction, remain central in patent infringement disputes concerning advanced imaging systems.
  • Technological distinctions and patent scope interpretation significantly influence infringement outcomes.
  • Companies should adopt proactive patent strategies, including routine prior art searches and clear claim amendments, to mitigate infringement risks.
  • Litigation outcomes can reshape industry standards for automated infrastructure monitoring, influencing future technological adoption and licensing habits.

FAQs

1. What are the main challenges Pavemetrics faces in defending their patent against Tetra Tech’s invalidity claims?

Pavemetrics must demonstrate that their patent claims are novel and non-obvious over prior art references cited by Tetra Tech. This involves detailed technical comparisons and expert testimony to establish that their innovations differ significantly from existing technologies at the filing date.

2. How does claim construction impact the infringement case?

Claim construction determines the scope of patent protection. Ambiguous or narrow interpretations can weaken infringement claims, while broader interpretations might risk invalidity. The court’s interpretation influences whether Tetra Tech’s systems fall within the patent claims.

3. Can Tetra Tech challenge the patent’s validity based on prior art?

Yes. Under 35 U.S.C. § 102 and § 103, Tetra Tech can argue that the patent is anticipated or was obvious based on prior publications or existing technologies. The success of these defenses depends on the strength of prior art evidence.

4. What strategic benefits do companies gain from patent litigation outcomes?

Successful enforcement solidifies market position and can lead to licensing revenues or injunctions. Conversely, invalidity findings discourage patent overreach but can weaken patent portfolio defenses, prompting strategic diversification.

5. How might this case influence future patent applications in automated rail inspection technologies?

The case highlights the necessity for detailed patent drafting that clearly delineates inventive features and includes comprehensive prior art searches. It also signals the importance of claims that withstand validity challenges, guiding future innovation and prosecution strategies.


References

[1] U.S. Patent No. [Number], Automated Rail Track Inspection System, filed [Year], granted [Year].

[2] U.S. Patent and Trademark Office, “Patent Trial and Appeal Board (PTAB) Proceedings,” 2022.


Disclaimer: The above analysis is for informational purposes only and not legal advice. For specific legal guidance, consult a qualified patent attorney.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.